DESCRIPTION (provided by applicant): Alzheimer's disease (AD) affects more than 5 million Americans, and this number is expected to nearly triple to more than 13 million by 2050 due to the growing population of older adults in our society. In Veterans, the overall prevalence of dementia among those treated at VA medical centers has been estimated at 7.3%. AD is the most common cause of dementia in Veterans aged 65 and older. Veterans may be at increased risk for AD relative to the general population due to the demographics of the Veteran population (e.g., older age) and the high prevalence of cardiovascular risk factors (e.g., hypertension, diabetes) which can increase risk for cognitive decline and dementia. As the number of Veterans diagnosed with AD increases dramatically in the coming years and decades, the costs associated with dementia care will also rise at alarming rates. The process of AD is believed to begin many years prior to the clinical diagnosis, and there is a need for enhanced detection and characterization of early phases of AD (i.e., mild cognitive impairment [MCI]). Previous studies have shown that AD and MCI are heterogeneous disorders that involve multiple underlying neuropathologies, including coexisting AD and cerebrovascular disease pathologies. Although there has been an increased focus on identifying sophisticated biomarkers indicative of early AD, methods of characterizing cognition in prodromal AD have remained relatively coarse. It has recently been established that the conventional method of diagnosing MCI is highly susceptible to diagnostic errors, while a novel actuarial neuropsychological method for MCI diagnosis significantly improves diagnostic accuracy. The goal of this Career Development Award (CDA-2) is for the candidate to develop the necessary skills to become an independent clinical scientist investigating cognitive and biomarker profiles associated with prodromal AD in Veterans. The application contains a research project aimed at identifying accurate and inaccurate MCI diagnoses in 84 older adult Veterans and characterizing participants in terms of their unique vascular and AD biomarker profiles. [The project will also examine "preclinical" AD, an asymptomatic phase of AD in which individuals are classified as cognitively normal yet test positive for biomarkers/cognitive markers associated with AD.] All participants will undergo a multimodal assessment at baseline and repeat neuropsychological evaluation at one-year intervals. Vascular biomarkers will include cerebrospinal fluid (CSF) markers of blood-brain barrier breakdown (i.e., cyclophilin A, matrix metalloproteinase 9, and a CSF/plasma albumin quotient ratio), and neuroimaging evidence of vascular pathology (i.e., white matter hyperintensities, cerebral microbleeds, reduced cerebral blood flow). AD biomarkers will include CSF concentrations of beta-amyloid, tau, and hyperphosphorylated tau, and neuroimaging markers of cortical thinning....